Marché mondial du diagnostic du cancer de la vessie – Tendances et prévisions de l’industrie jusqu’en 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché mondial du diagnostic du cancer de la vessie – Tendances et prévisions de l’industrie jusqu’en 2030

  • Medical Devices
  • Publish Reports
  • May 2023
  • Global
  • 350 Pages
  • Nombre de tableaux : 281
  • Nombre de figures : 69

Global Bladder Cancer Diagnostics Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
Dollars américains 3,900.60
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché mondial du diagnostic du cancer de la vessie, par type de test (cystoscopie, test de laboratoire d'urine, biopsie, test d'imagerie et autres), stades (stade I, stade II, stade III et stade IV), type de cancer (cancer de la vessie à cellules transitionnelles, cancer de la vessie à cellules squameuses et autres types de cancer), utilisateur final (hôpital, centres d'imagerie diagnostique, instituts de recherche sur le cancer, laboratoires de diagnostic indépendants et laboratoires associés), canal de distribution (appel d'offres direct et vente au détail) Tendances de l'industrie et prévisions jusqu'en 2030.

Marché du diagnostic du cancer de la vessie

Analyse et taille du marché du diagnostic du cancer de la vessie

Le marché mondial du diagnostic du cancer de la vessie est fragmenté par nature, car il se compose de nombreux acteurs mondiaux tels que F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV et Bio-Rad Laboratories, Inc., entre autres. La présence de ces entreprises produit des prix compétitifs pour le diagnostic du cancer de la vessie dans toute la région. En raison de la présence de ces acteurs aux niveaux régional et international, les fournisseurs et les fabricants proposent des produits avec des spécifications et des caractéristiques différentes pour tous les budgets. La prévalence croissante du cancer de la vessie à l'échelle mondiale stimule la croissance du marché. En outre, la sensibilisation croissante à la détection précoce du cancer de la vessie devrait stimuler la croissance du marché.

Marché du diagnostic du cancer de la vessieMarché du diagnostic du cancer de la vessie

Data Bridge Market Research estime que le marché mondial du diagnostic du cancer de la vessie devrait atteindre une valeur de 3 900,60 millions USD d'ici 2030, à un TCAC de 8,2 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Années historiques

2021 (personnalisable de 2015 à 2020)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Type de test (cystoscopie, test de laboratoire d'urine, biopsie, test d'imagerie et autres), stades (stade I, stade II, stade III et stade IV), type de cancer (cancer de la vessie à cellules transitionnelles, cancer de la vessie à cellules squameuses et autres types de cancer), utilisateur final (hôpital, centres d'imagerie diagnostique, instituts de recherche sur le cancer, laboratoires de diagnostic indépendants et laboratoires associés), canal de distribution (appel d'offres direct et vente au détail)

Pays couverts

États-Unis, Canada, Mexique, Allemagne, France, Royaume-Uni, Italie, Espagne, Pays-Bas, Russie, Suisse, Turquie, Belgique, Reste de l'Europe, Chine, Japon, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Reste de l'Asie-Pacifique, Brésil, Argentine, Reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël, Reste du Moyen-Orient et de l'Afrique

Acteurs du marché couverts

F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding et MinFound Medical Systems Co., entre autres

Définition du marché

Bladder cancer begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor. Urothelial cells also line the renal pelvis and ureters, and urethra. Cancer that develops in the renal pelvis and ureters is also considered a type of urothelial cancer and is often called upper tract urothelial cancer. In most cases, it is treated in much the same way as bladder cancer which is described in this guide. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Benign bladder tumors are very rare.

Global Bladder Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

Rising Incidence of Bladder Cancer Globally

Most gene mutations related to bladder cancer develop during a person's life rather than having been inherited before birth. Some of these acquired gene mutations result from exposure to cancer-causing chemicals or radiation. For instance, chemicals in tobacco smoke can be absorbed into the blood, filtered by the kidneys, and end up in urine, where they can affect bladder cells. Other chemicals may reach the bladder the same way. However, sometimes, gene changes may just be random events that sometimes happen inside a cell without having an outside cause.

Bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age of people when they are diagnosed is 73. The rising cases of bladder cancer among the population are enhancing the use of bladder cancer diagnostic products and hence driving the growth of the bladder cancer diagnostics market.

Rising Awareness for the Early Diagnosis of Bladder Cancer

Bladder cancer awareness month is nationally recognized in the U.S. during the month of May. It aims at bringing together the bladder tumor community to help raise awareness and shine a light on a patient population that is often overlooked. Although bladder cancer is not as common as breast or lung cancer, the need for new and innovative ways to treat bladder tumor patients has never been more critical. Research suggests that more than 720,000 patients in the U.S. are struggling with bladder cancer.

As the current global health crisis continues to shift with the impact of COVID-19, the importance of understanding the impacts of patient care, education, and cancer research is becoming more apparent than ever. Looking toward the future, there is still much more groundwork to be done in discovering new and effective drugs for bladder tumor patients, as well as a dire need for continuous education on a multitude of challenges we face when treating bladder cancer. 

Bladder cancer awareness month is a movement that is wholly dedicated to these efforts, and even in the midst of a pandemic, the need to help this patient population is still a top priority. Hence, the rising awareness of the early diagnosis of bladder cancer is driving the market's growth.

Marché du diagnostic du cancer de la vessie

OPPORTUNITY

Increase in Diagnostic Procedures for Bladder Cancer

Bladder cancer is among the top ten most common cancers globally, causes considerable morbidity and mortality, and is, therefore, a substantial burden for healthcare systems. Several techniques used to diagnose bladder cancer include ultrasound, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and, sometimes, Positron Emission Tomography (PET) scans.

Treatment for bladder cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. People prefer the treatment and getting diagnosed more. Also, the increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.

RESTRAINT / CHALLENGE

Side Effects of Bladder Cancer Treatment Drugs & Therapies

Chemotherapy (chemo) uses anti-cancer drugs that are usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach almost all areas of the body. However, many chemo drugs aren't able to enter the bladder and reach tumor cells. Bacillus Calmette-Guerin (BCG) is the most common intravesical immunotherapy for treating early-stage bladder cancer. BCG is a germ that's related to the one that causes Tuberculosis (TB), but it doesn't usually cause serious diseases. When BCG is put into the bladder as a liquid through a catheter, it helps "turn on" the immune system cells there, which then attack the bladder cancer cells.

Chemo drugs can cause side effects. These depend on the type and dose of drugs and how long treatment lasts. Common side effects can include hair loss, mouth sores, loss of appetite, nausea & vomiting, diarrhea, increased chance of infections (from having too few white blood cells), easy bruising or bleeding (from having too few blood platelets), fatigue (from having too few red blood cells, changes in metabolism or other factors). Some chemo drugs can also cause other, less common side effects. For instance, cisplatin and carboplatin can also cause kidney damage and hearing loss. Sometimes, the doses of the drugs may need to be reduced, or treatment may need to be delayed or stopped to prevent the effects from getting worse. Hence, the side effects of bladder cancer treatment drugs & therapies may restrain the growth of the Global bladder cancer diagnostics market.

Post-COVID-19 Impact on the Global Bladder Cancer Diagnostics Market

COVID-19 created a negative impact on the Global bladder cancer diagnostics market. The lockdown restriction led to the emergence of various challenges, such as decreased hospital visits and delays in treatment procedures.

The COVID-19 pandemic has impacted the market to an extent in a negative manner. However, increasing government support and advancements in imaging techniques are expected to provide lucrative opportunities for market growth. Moreover, increasing partnerships, acquisitions, and collaboration among market players are expected to further fuel market growth. Also, the growth has been high since the market opened after COVID-19, and it is expected that there will be considerable growth in the sector. The market players are conducting multiple activities to improve imaging techniques for the early detection of bladder cancer. With this, the companies will bring advancement and innovation to the market.

Recent Developments

  • In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company.
  • In January 2023, Thermo Fisher Scientific Inc. announced that it had completed the agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.

Global Bladder Cancer Diagnostics Market Scope

Global bladder cancer diagnostics market is segmented into five notable segments based test type, stages, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

  • Cystoscopy
  • Urine Lab Test
  • Biopsy
  • Imaging Test
  • Others

Based on test type, the market is segmented into cystoscopy, urine lab test, biopsy, imaging test, and others.

Stages

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Based on stages, the market is segmented into stage I, stage II, stage III, and stage IV.

Cancer Type

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

Based on cancer type, the market is segmented into transitional cell bladder cancer, squamous cell bladder cancer, and other cancer types.

End User

  • Hospital
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Independent Dignostic Laboratories
  • Associated Labs

Based on end user, the market is segmented into hospital, diagnostic imaging centers, cancer research institutes, independent diagnostic laboratories, and associated labs.

Distribution Channel

  • Direct Tender
  • Retail Sales

Based on distribution channel, the market is segmented into direct tender and retail sales.

Marché du diagnostic du cancer de la vessie

Global Bladder Cancer Diagnostics Market Regional Analysis/Insights

Le marché mondial du diagnostic du cancer de la vessie est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de test, stades, type de cancer, utilisateur final et canal de distribution comme référencé ci-dessus.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada, le Mexique, l'Allemagne, la France, le Royaume-Uni, l'Italie, l'Espagne, les Pays-Bas, la Russie, la Suisse, la Turquie, la Belgique, le reste de l'Europe, la Chine, le Japon, l'Inde, la Corée du Sud, l'Australie, Singapour, la Thaïlande, la Malaisie, l'Indonésie, les Philippines, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Arabie saoudite, les Émirats arabes unis, l'Égypte, Israël, le reste du Moyen-Orient et l'Afrique.

L'Amérique du Nord devrait dominer le marché mondial du diagnostic du cancer de la vessie avec la plus grande part de marché. Cette part est attribuable à la présence d'acteurs clés du marché tels que F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV et Bio-Rad Laboratories, Inc., entre autres. La prévalence croissante du cancer de la vessie et l'amélioration des techniques d'imagerie devraient alimenter la croissance du marché au cours de la période de prévision dans cette région.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Marché du diagnostic du cancer de la vessie

Analyse du paysage concurrentiel et des parts de marché mondiales du diagnostic du cancer de la vessie

Le paysage concurrentiel du marché mondial du diagnostic du cancer de la vessie fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Français Certains des principaux acteurs du marché opérant sur le marché mondial du diagnostic du cancer de la vessie sont F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding et MinFound Medical Systems Co., entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TEST TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.2 PORTER'S FIVE FORCES MODEL

5 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT

6 REGULATORY FRAMEWORK

6.1 REGULATORY SCENARIO IN THE U.S

6.2 REGULATORY SCENARIO IN JAPAN

6.3 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING INCIDENCE OF BLADDER CANCER GLOBALLY

7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER

7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY

7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER

7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES

7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS

7.3 OPPORTUNITIES

7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER

7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS

7.3.3 INCREASE IN THE GERIATRIC POPULATION

7.4 CHALLENGES

7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING

7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES

8 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 CYSTOSCOPY

8.3 URINE LAB TEST

8.3.1 URINE CYTOLOGY

8.3.2 URINALYSIS

8.3.3 URINE TUMOR MARKER TEST

8.3.4 URINE CULTURE

8.3.5 OTHERS

8.4 BIOPSY

8.5 IMAGING TEST

8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN

8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN

8.5.3 ULTRASOUND

8.5.4 INTRAVENOUS PYELOGRAM (IVP)

8.6 OTHERS

9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES

9.1 OVERVIEW

9.2 STAGE IV

9.3 STAGE III

9.4 STAGE II

9.5 STAGE I

10 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 TRANSITIONAL CELL BLADDER CANCER

10.3 SQUAMOUS CELL BLADDER CANCER

10.4 OTHER CANCER TYPES

11 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITAL

11.3 DIAGNOSTIC IMAGING CENTERS

11.4 CANCER RESEARCH INSTITUTES

11.5 INDEPENDENT DIAGNOSTIC LABORATORIES

11.6 ASSOCIATED LABS

12 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

13 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY REGION

13.1 OVERVIEW

13.2 NORTH AMERICA

13.2.1 U.S.

13.2.2 CANADA

13.2.3 MEXICO

13.3 EUROPE

13.3.1 GERMANY

13.3.2 FRANCE

13.3.3 U.K.

13.3.4 ITALY

13.3.5 SPAIN

13.3.6 RUSSIA

13.3.7 TURKEY

13.3.8 NETHERLANDS

13.3.9 BELGIUM

13.3.10 SWITZERLAND

13.3.11 REST OF EUROPE

13.4 ASIA-PACIFIC

13.4.1 CHINA

13.4.2 INDIA

13.4.3 JAPAN

13.4.4 SOUTH KOREA

13.4.5 THAILAND

13.4.6 SINGAPORE

13.4.7 INDONESIA

13.4.8 MALAYSIA

13.4.9 PHILIPPINES

13.4.10 AUSTRALIA

13.4.11 REST OF ASIA-PACIFIC

13.5 SOUTH AMERICA

13.5.1 BRAZIL

13.5.2 ARGENTINA

13.5.3 REST OF SOUTH AMERICA

13.6 MIDDLE EAST AND AFRICA

13.6.1 SOUTH AFRICA

13.6.2 SAUDI ARABIA

13.6.3 U.A.E

13.6.4 EGYPT

13.6.5 ISRAEL

13.6.6 REST OF MIDDLE EAST AND AFRICA

14 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

14.3 COMPANY SHARE ANALYSIS: EUROPE

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET

16.1 F. HOFFMANN- LA ROCHE LTD

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 MERCK KGAA

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 THERMO FISHER SCIENTIFIC INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 KONINLIJKE PHILIPS N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 BIO-RAD LABORATORIES, INC.

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SNAPSHOT

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 AGILENT TECHNOLOGIES, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 AMBU A/S

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BD

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 CANON MEDICAL SYSTEMS CORPORATION

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CEPHEID

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 FUJIFILM CORPORATION

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 GENERAL ELECTRIC COMPANY

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENTS

16.14 HOLOGIC INC.

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 ILLUMINA INC

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 MINFOUND MEDICAL SYSTEMS CO.,

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 NEUSOFT CORPORATION

16.17.1 COMPANY SNAPSHOT

16.17.2 COMPANY SNAPSHOT

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 QIAGEN

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 SIEMENS HEALTHCARE GMBH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TIME MEDICAL HOLDING.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

Liste des tableaux

TABLE 1 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 GLOBAL CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 GLOBAL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 GLOBAL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 GLOBAL STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 GLOBAL STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 GLOBAL CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 GLOBAL RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 36 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 U.S. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 U.S. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 39 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 40 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 41 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 42 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 43 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 CANADA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 45 CANADA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 47 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 48 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 49 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 50 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 51 MEXICO URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 52 MEXICO IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 54 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 55 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 57 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 58 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 59 EUROPE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 EUROPE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 62 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 63 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 64 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 65 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 GERMANY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 67 GERMANY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 68 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 69 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 70 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 71 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 72 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 FRANCE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 FRANCE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 76 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 77 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 78 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 79 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.K. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.K. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 83 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 85 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 86 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 ITALY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 ITALY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 90 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 92 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 93 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 SPAIN URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 SPAIN IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 96 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 97 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 98 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 99 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 100 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 RUSSIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 102 RUSSIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 103 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 104 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 105 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 106 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 107 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 TURKEY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 109 TURKEY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 110 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 111 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 112 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 113 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 114 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 115 NETHERLANDS URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 116 NETHERLANDS IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 117 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 118 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 119 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 120 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 121 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 BELGIUM URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 BELGIUM IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 125 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 126 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 127 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 128 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 SWITZERLAND URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 SWITZERLAND IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 131 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 132 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 133 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 134 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 135 REST OF EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 136 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 137 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 ASIA-PACIFIC URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 139 ASIA-PACIFIC IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 140 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 141 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 142 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 143 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 144 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 145 CHINA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 146 CHINA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 147 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 148 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 149 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 150 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 151 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 152 INDIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 153 INDIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 154 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 155 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 156 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 157 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 158 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 JAPAN URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 160 JAPAN IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 161 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 162 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 163 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 164 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 165 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 166 SOUTH KOREA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 SOUTH KOREA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 168 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 169 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 170 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 171 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 172 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 THAILAND URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 THAILAND IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 176 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 177 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 178 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 179 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 SINGAPORE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 181 SINGAPORE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 182 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 183 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 184 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 185 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 186 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 INDONESIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 188 INDONESIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 190 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 191 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 192 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 193 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 194 MALAYSIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 197 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 198 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 200 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 201 PHILIPPINES URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 202 PHILIPPINES IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 203 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 204 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 205 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 206 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 207 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 AUSTRALIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 AUSTRALIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 211 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 212 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 REST OF ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 215 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 216 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 217 SOUTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 SOUTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 219 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 220 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 221 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 222 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 223 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 BRAZIL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 BRAZIL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 227 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 228 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 229 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 230 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 231 ARGENTINA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 232 ARGENTINA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 233 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 234 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 235 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 236 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 237 REST OF SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 238 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 239 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 MIDDLE EAST AND AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 MIDDLE EAST AND AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 243 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 244 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 245 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 246 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 247 SOUTH AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 248 SOUTH AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 249 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 250 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 251 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 252 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 253 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 254 SAUDI ARABIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 255 SAUDI ARABIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 256 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 257 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 258 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 259 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 260 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 U.A.E. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 262 U.A.E. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 263 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 264 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 265 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 266 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 267 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 268 EGYPT URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 269 EGYPT IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 270 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 271 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 272 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 273 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 274 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 275 ISRAEL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 276 ISRAEL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 277 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 278 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 279 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 280 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 281 REST OF MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF BLADDER CANCER GLOBALLY IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR BLADDER CANCER DIAGNOSTICS MARKET SERVICE PROVIDERS IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET

FIGURE 16 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 17 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 18 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 19 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022

FIGURE 21 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 22 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 23 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE

FIGURE 24 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 25 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 26 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 27 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 29 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 30 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 31 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 33 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 34 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 35 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 36 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 37 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2022)

FIGURE 38 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030)

FIGURE 39 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030)

FIGURE 40 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030)

FIGURE 41 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 42 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 43 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 44 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 45 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 46 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 47 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 48 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 49 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 50 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 51 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 56 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 57 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 58 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 59 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 60 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 61 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 62 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 63 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 64 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 65 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 66 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

FIGURE 67 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

FIGURE 68 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

FIGURE 69 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Bladder Cancer Diagnostics Market is projected to grow at a CAGR of 8.2% during the forecast period by 2030.
The future market value of the Bladder Cancer Diagnostics Market is expected to reach USD 3,900.60 million by 2030.
The major players in the Bladder Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, etc.
The countries covered in the Bladder Cancer Diagnostics Market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, etc.